Yatharth Hospitals Gets CCI Approval for ₹3,150 Crore Advent Deal

Yatharth Hospital & Trauma Care Services Limited received Competition Commission of India approval on November 10, 2026, for Advent International’s proposed ₹3,150 crore primary investment, under which the private equity investor is expected to acquire a 24.9% minority stake in the hospital operator.

What did the CCI approve in the Yatharth Hospitals transaction?

The Competition Commission of India approved the proposed acquisition of certain shareholding in Yatharth Hospitals by Rasmalai Limited, the affiliate through which Advent International is making the investment. The approval removes a key competition-regulation hurdle for the transaction announced by the company in September.

The regulator confirmed its decision in a post on X, stating that the Commission had approved Rasmalai Limited’s acquisition of certain shareholding in Yatharth Hospital & Trauma Care Services Limited. The CCI said that a detailed order on the transaction would be issued separately.

Rasmalai Limited is described as Advent’s investment affiliate and special purpose vehicle. The deal is structured as a primary capital infusion into Yatharth Hospitals, rather than a transaction involving only the sale of shares by existing shareholders.

How will Advent International invest in Yatharth Hospitals?

Advent International will invest ₹3,150 crore in Yatharth Hospitals through Rasmalai Limited, with the transaction expected to result in a 24.9% holding for the private equity investor. Yatharth Hospitals announced the definitive agreement for the primary-capital investment on September 17, 2026.

The investment makes Advent a significant minority shareholder in the listed hospital company. The founding Tyagi family is expected to remain the largest shareholder after completion, preserving its position in the company’s ownership structure.

The transaction gives Advent additional exposure to India’s hospital and healthcare-services sector. For Yatharth Hospitals, the primary infusion is intended to provide growth capital for its stated expansion plans and for strengthening its healthcare network.

The CCI approval does not itself indicate that the share acquisition has been completed. It clears the proposed transaction under the competition-review process, while the Commission’s detailed order remains awaited.

Why does Yatharth Hospitals need growth capital?

Yatharth Hospitals operates nine multi-speciality hospitals with approximately 2,800 beds across its network. The Noida-based company provides super-speciality healthcare services, diagnostic facilities and advanced medical procedures across multiple medical disciplines.

The company has an overall announced capacity of 3,250 beds and has stated a plan to increase capacity to more than 5,000 beds over the next three years. The ₹3,150 crore primary infusion is intended to help fund this expansion and strengthen the hospital network.

Capacity growth is a central operational point in the transaction because hospital expansion typically requires investment in facilities, equipment and clinical infrastructure. The information disclosed on the deal identifies the capital as growth funding, but it does not set out a project-by-project allocation of the investment.

Yatharth Hospitals’ network and announced bed targets provide the operating context for Advent’s minority investment. The deal links a financial investor’s capital commitment with the company’s existing plan to add healthcare capacity.

What does CCI approval mean for investors and the hospital sector?

CCI approval means the competition regulator has cleared the proposed acquisition after reviewing it under the Competition Act, 2002. The Commission examines qualifying mergers and acquisitions to assess whether they could adversely affect competition in relevant markets in India.

For Yatharth Hospitals’ investors, the clearance moves the announced transaction closer to completion and confirms that the deal has passed an important regulatory stage. The expected 24.9% stake also indicates that Advent will be a minority shareholder, while the Tyagi family remains the largest shareholder.

For the hospital industry, the transaction adds to private equity activity in healthcare services. Advent’s proposed investment is directed at a company that operates nine hospitals and has disclosed a plan to expand beyond 5,000 beds within three years.

The available disclosures do not provide a completion date, detailed investment timetable or the CCI’s full reasoning. Those details may become clearer when the regulator publishes its detailed order and when the parties provide further transaction updates.

Conclusion

The CCI has cleared Rasmalai Limited’s proposed acquisition of a stake in Yatharth Hospitals, enabling Advent International’s ₹3,150 crore primary-capital investment to progress. If completed as announced, Advent is expected to hold 24.9%, while the founding Tyagi family will remain the company’s largest shareholder.

The next disclosures to watch are the CCI’s detailed order and updates on transaction completion. Yatharth Hospitals has stated that it plans to expand capacity to more than 5,000 beds over the next three years, making the use of the growth capital and progress toward that target important operational markers.